Brought to you by 
Pulmatrix, Ruthigen merge
02 Oct 2020
Executive Summary
Closely held Pulmatrix Inc. reverse merged with public biotech Ruthigen Inc. and will exchange its debt and equity for 81% of Ruthigen's outstanding shares. Each Pulmatrix share will be exchanged for 0.148187124066461 Ruthigen shares.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pulmatrix, Ruthigen merge
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice